Company news
Exicure, Inc. news in 2024
Exicure, Inc.'s news releases, calls and decks from 2024, newest first.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
December 25, 2024
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
December 23, 2024
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
December 19, 2024
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
November 13, 2024
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
September 17, 2024
Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
September 8, 2024
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
August 25, 2024
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
August 14, 2024
Exicure, Inc. Reports Second Quarter 2024 Financial Results
August 12, 2024
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
August 7, 2024
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
July 31, 2024
Exicure, Inc. Reports First Quarter 2024 Financial Results
June 16, 2024
Exicure, Inc. Reports Full Year 2023 Financial Results
June 5, 2024
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
May 22, 2024
Exicure, Inc. Reports Third Quarter 2023 Financial Results
May 15, 2024
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
February 4, 2024